Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:47PM ET
24.00
Dollar change
+0.66
Percentage change
2.83
%
IndexRUT P/E- EPS (ttm)-4.04 Insider Own0.69% Shs Outstand11.63M Perf Week-2.16%
Market Cap279.12M Forward P/E- EPS next Y-1.35 Insider Trans3.55% Shs Float11.55M Perf Month-3.81%
Income-46.30M PEG- EPS next Q-0.64 Inst Own65.01% Short Float2.38% Perf Quarter28.27%
Sales4.76M P/S58.64 EPS this Y57.30% Inst Trans0.91% Short Ratio11.46 Perf Half Y65.98%
Book/sh7.71 P/B3.11 EPS next Y21.45% ROA-21.79% Short Interest0.27M Perf Year13.10%
Cash/sh13.21 P/C1.82 EPS next 5Y19.00% ROE-38.39% 52W Range13.48 - 26.83 Perf YTD29.73%
Dividend Est.- P/FCF- EPS past 5Y-20.43% ROI-22.31% 52W High-10.55% Beta0.57
Dividend TTM- Quick Ratio8.68 Sales past 5Y46.25% Gross Margin79.05% 52W Low78.04% ATR (14)1.16
Dividend Ex-Date- Current Ratio8.68 EPS Y/Y TTM-104.25% Oper. Margin-460.03% RSI (14)49.53 Volatility4.53% 4.63%
Employees13 Debt/Eq1.40 Sales Y/Y TTM-21.06% Profit Margin-973.16% Recom2.00 Target Price74.00
Option/ShortYes / Yes LT Debt/Eq1.34 EPS Q/Q-191.80% Payout- Rel Volume0.59 Prev Close23.34
Sales Surprise-50.07% EPS Surprise-419.44% Sales Q/Q23.35% EarningsMar 08 BMO Avg Volume23.97K Price24.00
SMA20-3.62% SMA505.72% SMA20032.55% Trades Volume11,692 Change2.83%
Date Action Analyst Rating Change Price Target Change
Sep-07-21Downgrade Wedbush Outperform → Neutral $22
Jun-29-21Initiated Aegis Capital Buy $60
Jan-19-21Reiterated H.C. Wainwright Buy $30 → $56
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Mar-21-24 07:30AM
Mar-19-24 04:05PM
Mar-08-24 12:53PM
08:12AM
07:52AM
07:30AM Loading…
07:30AM
Feb-28-24 07:30AM
Feb-16-24 08:00AM
Jan-18-24 08:30AM
Jan-11-24 04:05PM
Jan-08-24 07:30AM
Jan-02-24 07:30AM
Dec-20-23 07:30AM
Dec-19-23 07:30AM
Nov-07-23 07:50AM
07:30AM Loading…
07:30AM
Oct-31-23 07:30AM
Sep-25-23 07:30AM
Sep-06-23 07:30AM
Aug-31-23 10:43PM
Aug-13-23 10:07AM
Aug-08-23 08:21AM
07:30AM
Jun-23-23 06:14PM
Jun-22-23 07:30AM
Jun-20-23 07:30AM
May-16-23 09:29AM
May-09-23 07:53AM
07:30AM
Apr-26-23 07:30AM
07:30AM Loading…
Mar-30-23 07:30AM
Mar-21-23 07:30AM
Mar-10-23 05:36AM
Mar-09-23 07:50AM
07:30AM
Mar-06-23 08:28AM
Feb-28-23 07:30AM
Jan-06-23 07:00PM
Jan-04-23 07:30AM
Dec-22-22 07:30AM
Dec-07-22 07:44AM
Nov-22-22 07:01AM
Nov-06-22 09:24AM
Nov-03-22 09:05AM
07:30AM
Sep-27-22 08:30AM
Sep-21-22 07:30AM
Sep-07-22 07:30AM
Sep-01-22 06:20AM
Aug-11-22 06:22AM
Aug-04-22 10:45AM
07:30AM
Jun-30-22 07:33AM
Jun-20-22 07:30AM
Jun-02-22 01:00AM
May-30-22 07:06AM
May-17-22 04:05PM
May-07-22 08:27AM
May-05-22 08:55AM
07:30AM
May-03-22 08:15AM
Apr-20-22 08:24AM
Mar-21-22 07:30AM
Mar-15-22 06:21AM
Mar-10-22 09:43AM
07:30AM
Mar-08-22 07:30AM
Mar-01-22 07:30AM
Feb-17-22 07:30AM
Jan-21-22 10:21AM
Dec-23-21 07:30AM
Dec-21-21 07:30AM
Dec-16-21 07:30AM
Nov-22-21 11:46AM
Nov-15-21 06:01AM
Nov-04-21 10:15AM
07:40AM
07:30AM
Oct-28-21 03:06PM
Oct-27-21 04:50AM
Oct-14-21 06:57AM
Oct-08-21 03:35AM
Sep-22-21 07:30AM
Sep-21-21 12:33PM
Sep-20-21 07:30AM
Sep-13-21 07:30AM
Sep-07-21 01:49PM
Aug-10-21 04:35PM
Aug-05-21 08:45AM
07:30AM
Jul-29-21 03:05PM
Jul-28-21 07:30AM
Jul-15-21 06:38AM
04:17AM
04:00AM
Jun-23-21 03:16PM
Jun-21-21 07:30AM
Jun-08-21 10:38AM
May-21-21 08:00AM
May-06-21 09:15AM
XOMA Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sitko BradleyChief Investment OfficerOct 03 '23Buy13.892503,4725,600Oct 04 04:30 PM
Sitko BradleyChief Investment OfficerOct 02 '23Buy14.251,50021,3755,350Oct 04 04:30 PM
Hughes OwenExec Chairman and Interim CEOOct 02 '23Buy13.831,00013,8303,500Oct 04 04:30 PM
Hughes OwenExec Chairman and Interim CEOSep 26 '23Buy14.432,49936,0612,500Sep 27 04:30 PM
Hughes OwenExec Chairman and Interim CEOSep 25 '23Buy14.651151Sep 27 04:30 PM
Sitko BradleyChief Investment OfficerMay 31 '23Buy17.131,50025,7003,500Jun 02 04:30 PM
Hughes OwenInterim CEOMay 24 '23Buy23.791,03224,5512,000May 25 04:30 PM
Hughes OwenInterim CEOMay 23 '23Buy23.4696822,706968May 25 04:30 PM
Sitko BradleyChief Investment OfficerMay 23 '23Buy19.0085016,1503,850May 25 04:30 PM
Sitko BradleyChief Investment OfficerMay 19 '23Buy19.501,00019,5003,000May 22 04:30 PM
Sitko BradleyChief Investment OfficerMay 16 '23Buy23.2050011,6022,000May 17 05:20 PM
Sitko BradleyChief Investment OfficerMay 15 '23Buy23.401,50035,1001,500May 16 04:13 PM
Sitko BradleyChief Investment OfficerMay 12 '23Buy18.992,00037,9852,000May 16 04:13 PM